MXPA05014200A - Tratamiento de la disfuncion sexual masculina. - Google Patents

Tratamiento de la disfuncion sexual masculina.

Info

Publication number
MXPA05014200A
MXPA05014200A MXPA05014200A MXPA05014200A MXPA05014200A MX PA05014200 A MXPA05014200 A MX PA05014200A MX PA05014200 A MXPA05014200 A MX PA05014200A MX PA05014200 A MXPA05014200 A MX PA05014200A MX PA05014200 A MXPA05014200 A MX PA05014200A
Authority
MX
Mexico
Prior art keywords
vasopressin
ejaculation
compound
receptors
treatment
Prior art date
Application number
MXPA05014200A
Other languages
English (en)
Spanish (es)
Inventor
Rachel Jane Russell
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MXPA05014200A publication Critical patent/MXPA05014200A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
MXPA05014200A 2003-07-23 2004-07-12 Tratamiento de la disfuncion sexual masculina. MXPA05014200A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0317227.7A GB0317227D0 (en) 2003-07-23 2003-07-23 Treatment of male sexual dysfunction
PCT/IB2004/002300 WO2005006899A1 (en) 2003-07-23 2004-07-12 Treatment of male sexual dysfunction

Publications (1)

Publication Number Publication Date
MXPA05014200A true MXPA05014200A (es) 2006-07-03

Family

ID=27772516

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05014200A MXPA05014200A (es) 2003-07-23 2004-07-12 Tratamiento de la disfuncion sexual masculina.

Country Status (12)

Country Link
EP (1) EP1656183B1 (cg-RX-API-DMAC7.html)
JP (1) JP2006528171A (cg-RX-API-DMAC7.html)
AT (1) ATE380048T1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0412255A (cg-RX-API-DMAC7.html)
CA (1) CA2533177A1 (cg-RX-API-DMAC7.html)
CL (1) CL2004001702A1 (cg-RX-API-DMAC7.html)
GB (1) GB0317227D0 (cg-RX-API-DMAC7.html)
MX (1) MXPA05014200A (cg-RX-API-DMAC7.html)
TW (1) TW200510424A (cg-RX-API-DMAC7.html)
UA (1) UA79674C2 (cg-RX-API-DMAC7.html)
WO (1) WO2005006899A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200505957B (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1663978T3 (pl) 2003-07-23 2008-04-30 Bayer Healthcare Llc Fluoropodstawiony omega-karboksyarylodifenylomocznik do leczenia i profilaktyki chorób i stanów
GB0504556D0 (en) * 2005-03-04 2005-04-13 Pfizer Ltd Novel pharmaceuticals
JP2008533192A (ja) * 2005-03-21 2008-08-21 ファイザー・リミテッド オキシトシンアンタゴニストとしての置換されたトリアゾール誘導体
US20220152032A1 (en) * 2020-11-13 2022-05-19 Pharma America Holding Inc. Sexual therapy formulation and method of treatment
CN117414361B (zh) * 2023-09-28 2026-08-07 华中农业大学 一种化合物在预防和治疗革兰氏阴性菌病方面的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2000223275A1 (en) * 2000-02-08 2001-08-20 Yamanouchi Pharmaceutical Co..Ltd. Novel triazole derivatives
GB0224919D0 (en) * 2002-10-25 2002-12-04 Pfizer Ltd Triazole compounds useful in therapy

Also Published As

Publication number Publication date
CL2004001702A1 (es) 2005-05-13
CA2533177A1 (en) 2005-01-27
UA79674C2 (en) 2007-07-10
EP1656183A1 (en) 2006-05-17
ATE380048T1 (de) 2007-12-15
WO2005006899A1 (en) 2005-01-27
BRPI0412255A (pt) 2006-09-19
TW200510424A (en) 2005-03-16
ZA200505957B (en) 2006-11-29
GB0317227D0 (en) 2003-08-27
JP2006528171A (ja) 2006-12-14
EP1656183B1 (en) 2007-12-05

Similar Documents

Publication Publication Date Title
TW477792B (en) Modified amino acids, medicaments containing these compounds and processes for their preparation
EP1827444B1 (en) Mnk1 or mnk2 inhibitors
CN106536520B (zh) 芳基受体调制剂及其制备和使用方法
RU2734261C2 (ru) Необязательно конденсированные гетероциклилзамещенные производные пиримидина, пригодные для лечения воспалительных, метаболических, онкологических и аутоиммунных заболеваний
AU3873401A (en) Compositions and methods for treating female sexual dysfunction
US8329656B2 (en) Use of a PDE5 inhibitor for treating and preventing hypopigmentary disorders
JP2002541258A (ja) インターリューキン−12シグナルを阻害するための治療用化合物及びその使用方法
RS54261B1 (sr) Upotreba sgc stimulatora, sgc aktivatora, pojedinačno i u kombinaciji sa pde5 inhibitorima za tretman sistemske skleroze (ssc)
US20230374143A1 (en) A sortilin antagonist for use in the prevention or treatment of hearing loss
JP2018076360A (ja) 癌、自己免疫性炎症及びcns疾患の処置のためのビフルオロジオキサラン−アミノ−ベンゾイミダゾールキナーゼ阻害剤
TW201120042A (en) N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline forms and processes
JP2007517857A (ja) 治療に有用な化合物
US20050049255A1 (en) Therapeutic combinations
JP2005519927A (ja) 多嚢胞性卵巣症候群の処置における、シルデナフィル如きpde5インヒビターの使用
US20240189315A1 (en) Cyclic Pyridine Derivatives as cGAS Inhibitors
US20020091129A1 (en) Treatment of premature ejaculation
EP1656183B1 (en) Treatment of male sexual dysfunction
JP2008150371A (ja) 性機能障害を治療するための化合物
US20080139628A1 (en) Compositions For Treating Flushing And Lipid-Associated Disorders Comprising Niacin Receptor Partial Agonists
US20050026810A1 (en) Treatment of male sexual dysfunction
AU2003242895A1 (en) Combination of PDE5 inhibitors with angiotensin II receptor antagonists
KR100595807B1 (ko) 조루 치료법
JP2007518788A (ja) バソプレッシンのアンタゴニスト活性を阻害するトリアゾール誘導体
ES2313626T3 (es) Derivados de triazol sustituidos como antagonistas de oxitocina.
EP1759700A1 (en) Use of a PDE5 inhibitor for treating and preventing hypopigmentary disorders